Hiem Thong, MD
Internal Medicine · Savannah, GANPI 1184623993
Payments from drug & device makers
Across 265 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$890
- Novartis$353
- Pfizer$328
- AstraZeneca$288
- Amgen$260
- AbbVie$240
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,85098%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $890 |
| Novartis | 25 | $353 |
| Pfizer | 25 | $328 |
| AstraZeneca | 19 | $288 |
| Amgen(2 entities) | 18 | $260 |
| AbbVie(2 entities) | 19 | $240 |
| Lilly USA, LLC | 10 | $146 |
| Bayer | 8 | $145 |
| Esperion Therapeutics, Inc. | 8 | $134 |
| Boehringer Ingelheim | 7 | $126 |
| Cook Medical LLC | 1 | $124 |
| Merck | 8 | $120 |
| Astellas Pharma US Inc | 2 | $82 |
| Johnson & Johnson | 5 | $78 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Mannkind Corporation | 2 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Nevro Corp. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| GSK | 2 | $32 |
| Eisai Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Pacira Therapeutics, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilver PTX$124
How this compares
$3,915 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 142 | $157,036 |
| OzempicSemaglutide | 133 | $145,222 |
| EliquisApixaban | 117 | $97,298 |
| RybelsusSemaglutide | 55 | $95,487 |
| TrulicityDulaglutide | 35 | $67,656 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $58,302 |
| JanuviaSitagliptin Phosphate | 39 | $55,365 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $47,716 |
| MounjaroTirzepatide | 40 | $43,965 |
| LinzessLinaclotide | 35 | $33,420 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $29,089 |
| MyrbetriqMirabegron | 31 | $24,431 |
| EntrestoSacubitril/Valsartan | 18 | $23,001 |
| FarxigaDapagliflozin Propanediol | 43 | $22,549 |
| VascepaIcosapent Ethyl | 21 | $19,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $890 | $240,709188 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $126 | $178,704172 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $146 | $111,62175 claims |
| PfizerEliquis | $328 | $97,298117 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $32 | $92,194169 claims |
| MerckJanuvia | $120 | $55,36539 claims |
| AbbVieLinzess | $240 | $33,42035 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $24,43131 claims |
| NovartisEntresto | $353 | $23,00118 claims |
| AstraZenecaFarxiga | $288 | $22,54943 claims |
| Johnson & JohnsonXarelto | $78 | $14,93511 claims |
| BayerKerendia | $145 | $9,63011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Savannah
- Paul BradleySavannah$76.4M
- Thomas MoriaritySavannah$4.6M
- Nancy BackusSavannah$1.2M
- Robert RemlerSavannah$255K
- Jennifer WoehlerSavannah$207K
- Brooke HalpernSavannah$185K
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.